News
/NewsCenter.html

Humanwell Healthcare makes pharmaceutical intermediates, raw materials, excipients and preparations, including narcotic drugs, steroid hormones and Uyghur medicine.
humanwell.com.cnCrawled Nov 22, 2026
Humanwell Healthcare (Group) Co.
Humanwell Healthcare, a $4.2 billion pharmaceutical company in China, faces a CNY 36.7 million ($5 million) fine for past misconduct, including the misappropriation of billions in funds. The company was previously controlled by the collapsed Wuhan Dangdai Science & Technology Industries Group.
Ai Luming constructed a pharmaceutical business specializing in fentanyl-related products, leveraging debt and expansion to dominate the market. Regulatory crackdowns, financial mismanagement, and corruption allegations triggered a collapse, leaving the empire insolvent. The case highlights vulnerabilities in China’s private sector amid stricter oversight and economic instability.
Ai Luming, known as China’s ‘Fentanyl King,’ built a billion-dollar conglomerate from a 2,000 yuan urine collection business with the help of key partners. His empire now faces bankruptcy restructuring amid allegations of corruption. At a private dinner before the court-approved process, Ai reflected on his past with emotional vulnerability.
Humanwell and PuraCap have acquired Epic Pharma in a $550 million deal. The acquisition aims to strengthen their commercial operations, manufacturing capabilities, and market position in the U.S. generics pharmaceutical sector.
Humanwell Healthcare Group and PuraCap Pharmaceutical LLC have agreed to acquire Epic Pharma, LLC for $550 million. The deal secures full ownership of the New York-based company, strengthening their presence in the US generics pharmaceutical market. The acquisition also expands their commercial and manufacturing operations.